


# Supporting Manufacturing, Trade and Equitable Global Access to COVID-19 Vaccines



Equitable distribution was our North Star from day one. In order to ensure that every country that chooses the Pfizer-BioNTech COVID-19 vaccine can have access to it, **two conditions** had to be met: **a price that all countries can afford** and **reliable manufacturing to enable broad global distribution**.

To date (09 January 2022), Pfizer and BioNTech have shipped **more than 2.66 billion vaccines to 167 countries and territories around the world**, including:



Pfizer and BioNTech produced **3 billion doses worldwide in 2021**.

We expect to produce **4 billion doses in 2022**.

We have **pledged to provide 2 billion doses of our COVID-19 vaccine to low- and middle-income countries in 2021 and 2022** – at least 1 billion doses each year.

**On 29 December 2021, Pfizer and BioNTech fulfilled this pledge for 2021**, having delivered more than **1 billion doses to 99 of these countries**.

We will continue to partner with governments and the global health community to supply **at least another 1 billion doses** to these countries in 2022.



## Supply Pathways:

- Direct supply agreements to governments.
- Direct supply agreement with COVAX for 40 million doses in 2021.
- Government donation programs – via COVAX & directly.
  - o This includes 1 billion doses to the US at a not-for-profit price for low- and lower-middle-income countries and the African Union.
- Targeted humanitarian donation programs.



## Tiered Pricing Policy:

- During the pandemic we are pricing our vaccine in a way that can help governments ensure that there is little to no out-of-pocket cost for their populations.
- The price for wealthier nations would be equivalent to the cost of a takeaway meal.
  - Middle income countries are offered our COVID-19 vaccine at half this price.
  - Low and lower-middle income countries are offered doses at a not-for-profit price.

With our industry partners, we also share the five commitments<sup>1</sup> to urgently advance vaccine equity:



**Step up dose sharing**



**Continue to optimize production**



**Call out trade barriers to be eliminated**




**Support country readiness**




**Drive innovation**

# Fundamental to our access strategy is work to globally scale up manufacturing.

From the outset, we have taken a **relentless focus on efficiency** to enable us to quickly scale up manufacturing. Reducing production timelines has been achieved by:



We are also **partnering to build up scale**. The Pfizer-BioNTech global COVID-19 vaccine supply chain and manufacturing network now spans **four continents** and includes more than **20 facilities**.



**We select partners** using a rigorous process based on several factors, including: quality, compliance safety track record, technical capability, capacity availability, highly trained workforce, project management abilities, and prior working relationship.

Steps involved in a **tech transfer** process for a new facility include: on-site development, equipment installation, engineering and process qualification tests, and regulatory approvals.

Pfizer and BioNTech will **continue to explore and pursue opportunities** to bring new partners into our supply chain network to further accelerate access to the COVID-19 vaccine.

## Recommendations for policymakers:

### Support open trade.

The vaccine manufacturing process depends on a complex global network of suppliers, competing for raw materials and equipment. Trade bottlenecks – including export restrictions, regulatory barriers, tariffs, and customs red tape – add uncertainty, cost, and delay to both manufacturing and patient access.

### Invest in country readiness.

Vaccine deployment requires scale up of ultra-cold chain capacity, trained health care personnel, and more resilient health system infrastructure to broadly support delivery, particularly in low and lower-middle income countries. In addition, issues with demand and vaccine confidence are faced in some countries.

### Enable innovation.

Manufacturers are engaged in unprecedented collaboration to support R&D and manufacturing, thanks in large part to intellectual property (IP) protections and other pro-innovation policies. R&D continues to be needed for special populations (e.g. children), tackling new variants, developing additional therapeutics, and preparing for future pandemics.

<sup>i</sup> <https://www.ifpma.org/wp-content/uploads/2021/05/News-Release-Five-steps-to-urgently-advance-COVID-19-vaccine-equity-19-May-2021.pdf>

<sup>ii</sup> Including plasmid DNA, nucleotides, capping agents, and lipids.